quantisnow
FeedTopReportsPricing
⌘K
Live feed
07:25:00·8d
PRRelease
Alterity Therapeutics Limited logo

Alterity Therapeutics to Host Virtual KOL Event to Share New Insights on ATH434 for the Treatment of Multiple System Atrophy

ATHE· Alterity Therapeutics Limited
Health Care
Original source

Companies

  • ATHE
    Alterity Therapeutics Limited
    Health Care

Recent analyst ratings

  • Feb 3UpdateThe Benchmark Company-
  • Dec 12UpdateMaxim Group$8.00
  • Aug 20UpdateBenchmark$4.00

Related

  • PR1d
    Alterity Therapeutics Presents New Analysis of ATH434 Phase 2 Trial Data in Late Breaking Science Session of the American Academy of Neurology
  • SEC1d
    SEC Form 6-K filed by Alterity Therapeutics Limited
  • SEC3d
    SEC Form 6-K filed by Alterity Therapeutics Limited
  • SEC3d
    SEC Form 6-K filed by Alterity Therapeutics Limited
  • SEC3d
    SEC Form 6-K filed by Alterity Therapeutics Limited
  • PR6d
    Alterity Therapeutics Appoints Highly Experienced Biotech Executive Ann Cunningham to its Board of Directors
  • SEC7d
    SEC Form 6-K filed by Alterity Therapeutics Limited
  • PR7d
    Alterity Therapeutics Announces Late-Breaker Oral Presentation at the American Academy of Neurology Annual Meeting
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022